Boehringer's leukemia candidate wins breakthrough status from FDA

09/19/2013 | Healio · PharmaTimes (U.K.)

Boehringer Ingelheim's pololike kinase inhibitor volasertib won breakthrough-therapy designation from the FDA as a potential treatment for acute myeloid leukemia. The approval was based on data from a midstage trial that showed volasertib, in combination with low-dose cytarabine, improved overall and event-free survival compared with cytarabine alone.

View Full Article in:

Healio · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD